BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10037012)

  • 1. Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections.
    Itälä M; Pelliniemi TT; Remes K; Vanhatalo S; Vainio O
    Leuk Lymphoma; 1998 Dec; 32(1-2):165-74. PubMed ID: 10037012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection.
    Bodey GP; Anaissie E; Gutterman J; Vadhan-Raj S
    Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 2():S18-22. PubMed ID: 7875147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human GM-CSF treatment of neutropenia in glycogen storage disease-1b.
    Hurst D; Kilpatrick L; Becker J; Lipani J; Kleman K; Perrine S; Douglas SD
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):71-6. PubMed ID: 8447561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) on chemotherapy-induced myelosuppression in patients with chronic lymphocytic leukemia: a crossover study.
    Itälä M; Vanhatalo S; Remes K
    Leuk Lymphoma; 1997 May; 25(5-6):503-8. PubMed ID: 9250821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM-CSF treatment in patients with B-chronic lymphocytic leukemia.
    de Nully Brown P; Hansen MM
    Leuk Lymphoma; 1999 Jan; 32(3-4):365-8. PubMed ID: 10037035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of neutropenia associated with chronic lymphocytic leukaemia following treatment with granulocyte-macrophage colony-stimulating factor.
    Hollander AA; Kluin-Nelemans HC; Haak HR; Stern AC; Willemze R; Fibbe WE
    Ann Hematol; 1991 Feb; 62(1):32-4. PubMed ID: 2031965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia.
    Itälä M; Vainio O; Remes K
    Eur J Haematol; 1996 Jul; 57(1):46-53. PubMed ID: 8698131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [GM-CSF and G-CSF: cytokines in clinical application].
    Ruef C; Coleman DL
    Schweiz Med Wochenschr; 1991 Mar; 121(12):397-412. PubMed ID: 1709294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Dinçol D; Samur M; Pamir A; Sencan O; Akbulut H; Yalçin B; Onur H; Demirkazik A; Senler FC; Içli F
    Cancer; 2000 May; 88(9):2033-6. PubMed ID: 10813713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases.
    Rose C; Wattel E; Bastion Y; Berger E; Bauters F; Coiffier B; Fenaux P
    Leukemia; 1994 Sep; 8(9):1458-62. PubMed ID: 8090025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial.
    Uyl-de Groot CA; Vellenga E; de Vries EG; Löwenberg B; Stoter GJ; Rutten FF
    Pharmacoeconomics; 1997 Sep; 12(3):351-60. PubMed ID: 10170460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
    N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
    Liang DC
    Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of granulocyte macrophage colony stimulating factor in children after orthotopic liver transplantation.
    Trindade E; Maton P; Reding R; de Ville de Goyet J; Otte JB; Buts JP; Sokal EM
    J Hepatol; 1998 Jun; 28(6):1054-7. PubMed ID: 9672183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
    Thomas X; Boiron JM; Huguet F; Reman O; Sutton L; Turlure P; Garban F; Gardin C; Espinouse D; Boulat O; Lhéritier V; Fiere D;
    Hematol J; 2004; 5(5):384-94. PubMed ID: 15448664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.